Reuters logo
Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial
October 1, 2014 / 10:19 AM / 3 years ago

Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial

Oct 1 (Reuters) - Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared to a placebo in a mid-stage study involving 371 patients.

Ardelyx licensed the drug, tenapanor, to AstraZeneca Plc in October 2012.

The companies are also testing the drug for two kidney-related indications. (Reporting by Amrutha Penumudi in Bangalore; Editing by Ted Kerr)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below